False-Positive Buprenorphine by CEDIA in Patients Prescribed Amisulpride or Sulpiride

M.A. Birch1, L. Couchman1, S. Pietromartire2, T. Karna2, C. Paton3, R. McAllister3, A. Marsh1 and R.J. Flanagan1

1Toxicology Unit, Department of Clinical Biochemistry, King’s College Hospital, London, SE5 9RS, 2Cambian Churchill Hospital, Lambeth Road, London, SE1 7PW, and 3Bracton Centre, Leyton Cross Road, Dartford, DA2 7AP

Buprenorphine is a potent partial opioid agonist that is analyzed in urine to (i) monitor adherence to maintenance or detoxification therapy and (ii) detect illicit use. Buprenorphine analysis is commonly conducted on urine by immunoassay, but is subject to cross-reactivity from other drugs/drug metabolites, including morphine, codeine and dihydrocodeine. This study reports false-positive buprenorphine analysis [Thermo Fisher Scientific cloned enzyme donor immunoassay (CEDIA)] in patients who denied unauthorized buprenorphine use prior to sampling, but who had been prescribed amisulpride. In two cases, confirmatory analysis by liquid chromatography–tandem mass spectrometry was negative (<0.5 μg/L) for buprenorphine and metabolites and positive for amisulpride. Although the cross-reactivity of amisulpride and sulpiride in the CEDIA buprenorphine assay is low (estimated at 0.003 and 0.002%, respectively), it remains a significant consideration given the likely high concentrations of these compounds in urine relative to the low cutoff of the buprenorphine assay. Neither amisulpride nor sulpiride was listed as potential sources of interference on the CEDIA datasheet when this work was performed. These findings highlight the importance of confirming immunoassay-positive buprenorphine results using a more selective analytical technique.

Methods

Buprenorphine, norbuprenorphine, buprenorphine glucuronide, norbuprenorphine glucuronide, buprenorphine-D4 and norbuprenorphine-D3 were from LGC Standards (Teddington, UK). (±)-Amisulpride, (±)-sulpiride and β-gluconuronidase (Helix pomatia) were from Sigma Aldrich (Poole, UK). CEDIA reagents were supplied through Thermo Fisher Scientific.

CEDIA assays

Urine samples were processed for opiates, methadone metabolite (EDDP), cocaine, benzodiazepines, barbiturates, amphetamines, cannabinoids and buprenorphine according to the manufacturer’s instructions by using an automated analyzer (Olympus AU640, Beckman Coulter, UK). Sample integrity was assessed by the measurement of creatinine (Jaffé method) using the same analyzer.

HPLC–UV and LC–MS-MS

Urinary total (free and conjugated) buprenorphine and norbuprenorphine were measured using solid-phase extraction (SPE), followed by liquid chromatography–tandem mass spectrometry (LC–MS-MS). Briefly, samples were analyzed by mixed-mode SPE (Phenomenex Strata Screen CTM columns) before and after hydrolysis (β-glucuronidase in 1.0 mmol/L sodium acetate; pH 5.0, 37°C, 12 h). The eluate was evaporated to dryness under a stream of nitrogen (40°C), and reconstituted in methanol. Extracts were analyzed using isocratic strong cation exchange (SCX) high-performance liquid chromatography (HPLC; Waters Spherisorb S5SCX), followed by positive mode atmospheric pressure chemical ionization (APCI)–MS–MS (TSQ Quantum Access, Thermo Fisher Scientific) (10). This method was cross-validated using Healthcontrol Drugs of Abuse Scheme external quality assessment (EQA) samples (Sample numbers: 238, 247–249) containing various concentrations of buprenorphine and buprenorphine metabolites.
Clinical Background

Patient 1

A 31-year-old male with a long history of solvent, alcohol and illicit substance misuse had been diagnosed with paranoid schizophrenia at the age of 18. Treatment was complicated by occasional methadone and heroin use. A urine drug screen in a local laboratory (CEDIA) was positive for buprenorphine. He admitted to regular cannabis use and frequent heroin use until five weeks before the urine test. He also admitted occasional alcohol use, but consistently denied using buprenorphine, or awareness that it was or had been available at the center where he was being treated.

Patient 2

A 30-year-old male started using illicit heroin at the age of 17. Some seven years later, he started buprenorphine (Subutex) maintenance therapy, but methadone was substituted after he was found to be injecting buprenorphine. Aged 28, he was prescribed amisulpride. A year later, the prescribed amisulpride dose was 600 mg/d. He admitted to occasional illicit heroin use while on methadone, but relapsed into more regular heroin use and methadone prescription was discontinued. Aged 29, he was prescribed buprenorphine: 2 mg/d for five days. He discharged himself from the detoxification clinic and over the next three days said he used illicit buprenorphine (reported as 2 mg/d) and benzodiazepines. He was subsequently admitted to the hospital, and over the ensuing months discharged himself and was re-admitted many times, but claimed that, other than smoking cannabis and drinking alcohol, he did not take illicit drugs, including buprenorphine. However, a random urine sample tested positive for buprenorphine (CEDIA) at a local laboratory.

Patient and external quality assessment samples

Random urine samples from Patients 1 and 2, and from further patients prescribed amisulpride, but not buprenorphine, were supplied for analysis. At the time of sampling, Patient 1 was prescribed clozapine (800 mg/d), amisulpride (150 mg/d), venlafaxine (300 mg/d), hyoscine hydrobromide (600 µg/d), metformin (2,550 mg/d), gliclazide (20 mg/d), simvastatin (40 mg/d), fenofibrate (160 mg/d) and aspirin (75 mg/d), and admitted to using cannabis; Patient 2 was prescribed amisolpride (600 mg/d), diazepam (12.5 mg/d), zopiclone (15 mg/d) and diclofenac (50 mg/d), and admitted to using cannabis. HeathControl Drugs of Abuse Scheme (LGC Standards) urinary buprenorphine EQA specimens were analyzed as appropriate.

Assessment of amisulpride and sulpiride CEDIA cross-reactivity

Urine from a healthy volunteer that tested negative for buprenorphine on CEDIA was reanalyzed using this same technique after the addition of amisulpride or sulpiride (50–1,000 mg/d of each compound). The relative concentrations at which the cross-reactants provided an apparent CEDIA buprenorphine concentration > 5 µg/L were used to estimate percentage cross-reactivity for each compound.

Results

The results obtained on the analysis of the samples were as follows. Patient 1: creatinine, 2.6 mmol/L; CEDIA buprenorphine, < 5 µg/L; LC–MS–MS buprenorphine and norbuprenorphine (total, i.e., after hydrolysis of conjugates), both < 0.5 µg/L; and HPLC–UV amisulpride, 22 µg/L. Patient 2: creatinine, 20.1 mmol/L; CEDIA buprenorphine, 8.0 µg/L; LC–MS–MS buprenorphine and norbuprenorphine (total, i.e., after hydrolysis of conjugates); both < 0.5 µg/L; LC–MS–MS amisulpride, > 5 µg/L (after 10-fold dilution in deionized water). In both cases, CEDIA was positive for cannabinoids; for Patient 2, benzodiazepines were also present. All other CEDIA assays were negative.

Of nine urine samples from three patients prescribed amisulpride, but not buprenorphine, three (HPLC–UV amisulpride concentrations of 7–22 mg/L) showed apparent buprenorphine concentrations < 5 µg/L on CEDIA. The remaining samples (HPLC–UV amisulpride concentrations of 168–1,380 mg/L) provided apparent buprenorphine results of 5–46 µg/L on CEDIA. The highest of these results was from a sample from a patient prescribed 1,200 mg/d of amisulpride.

A urine sample from a patient prescribed 600 mg/d of sulpiride (Heathcontrol sample number 275) showed an apparent buprenorphine result (CEDIA) of 11.5 µg/L. The same sample was negative for buprenorphine, norbuprenorphine and conjugated metabolites by LC–MS–MS, but had a sulpiride concentration > 5 mg/L when analyzed by LC–MS–MS after 10-fold dilution in deionized water.

CEDIA cross-reactivity

The analysis of urine to which amisulpride or sulpiride had been added showed positive cross-reactivity on the CEDIA buprenorphine assay (approximately 0.003 and 0.002%,...
Discussion

Neither amisulpride nor sulpiride were listed as potential cross-reactants in the CEDIA buprenorphine immunoassay when this work was undertaken. Amisulpride and sulpiride are usually given orally at doses in the range 400–1,200 and 600–1,600 mg/d, respectively (12), and are excreted largely unchanged (95%) in urine and bile (3). Although the cross-reactivity of these compounds in the CEDIA buprenorphine assay was very low (estimated at 0.003 and 0.002% for amisulpride and sulpiride, respectively), cross-reactivity remains a significant consideration, given the likely high concentrations of these compounds in urine from patients prescribed these drugs (of the order of 1 g/L). The absence of all analytes (limit of detection: 0.5 μg/L) in urine to which norbuprenorphine was added (1,000 μg/L) gave an apparent CEDIA buprenorphine result of 0.6 μg/L.

Conclusions

CEDIA remains a useful tool with which to monitor urine from clients prescribed buprenorphine, or if buprenorphine abuse is suspected, because the assay is rapid and simple to perform. However, particular caution is needed when interpreting weakly positive results (5–30 μg/L), because such results may be achieved by cross-reactivity from opioids or other drugs alone. A selective method such as LC–MS-MS can be used not only in confirmation work, but also when monitoring the later stages of opioid detoxification therapy when total buprenorphine in urine is low. The ability to detect norbuprenorphine and norbuprenorphine glucuronide is valuable in such circumstances, and also serves to increase the detection window from the time of last use.

Acknowledgments

The authors wish to thank Heathcontrol at LGC Standards and Mr. Brian Smith for permission to use EQA data.

References